The Prevalence of Hepatitis B Surface Antigen and Anti-Hepatitis B Core Antibody in Iran: A Population-Based Study

被引:0
作者
Merat, Shahin [1 ]
Rezvan, Houri [2 ]
Nouraie, Mehdi [1 ,3 ,4 ]
Jamali, Arsia [1 ]
Assari, Shervin [5 ]
Abolghasemi, Hassan [2 ]
Radmard, Amir-Reza [1 ]
Zaer-Rezaii, Hanieh [1 ]
Zeid-Abadi-Nejhad, Mahmood [6 ]
Hosseini, Mohammad-Reza [6 ]
Amini-Kafiabad, Sedigheh [2 ]
Maghsudlu, Mahtab [2 ]
Pourshams, Akram [1 ]
Malekzadeh, Reza [1 ]
机构
[1] Sharitai Hosp, Digest Dis Res Ctr, Tehran 14117, Iran
[2] Iran Blood Transfus Org Res Ctr, Tehran, Iran
[3] Howard Univ, Dept Internal Med, Washington, DC 20059 USA
[4] Ctr Sickle Cell Dis, Washington, DC USA
[5] Med & Hlth Promot Inst, Tehran, Iran
[6] NAJA Khatam ol Anbia Hosp, Bandar Abbas, Iran
关键词
Hepatitis B virus; Iran; prevalence; INFECTIONS; EPIDEMIOLOGY; PROVINCE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hepatitis B virus infection is a very common cause of chronic liver disease worldwide. It is estimated that 3% of Iranians are chronically infected with hepatitis B virus. Current population-based studies on both rural and urban prevalence of hepatitis B virus infection in Iran are sparse with results that do not always agree. We performed this study to find the prevalence of hepatitis B surface antigen, anti-hepatitis B core antibody, and associated factors in the general population of three provinces of Iran. Methods: We randomly selected 6,583 subjects from three provinces in Iran, namely Tehran, Golestan, and Hormozgan. The subjects were aged between 18 and 65 years. Serum samples were tested for hepatitis B surface antigen and anti-hepatitis B core antibody. Various risk factors were recorded and multivariate analysis was performed. Results: The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran was 2.6% and 16.4%, respectively. Predictors of hepatitis B surface antigen or anti-hepatitis B core antibody in multivariate analysis included older age, not having high-school diploma, living in a rural area, and liver disease in a family member. We did not find any significant differences between males and females. Conclusion: in spite of nationwide vaccination of newborns against hepatitis B virus since 1992, hepatitis B virus infection remains a very common cause of chronic liver disease in Iran which should be dealt with for at least the next 30 - 50 years.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 30 条
  • [1] AALI BS, 1997, J KERMAN U MED SCI, V6, P89
  • [2] Alizadeh A. H. M., 2006, Eastern Mediterranean Health Journal, V12, P528
  • [3] AMINI S, 1993, J TROP MED HYG, V96, P277
  • [4] AMINIKAFIABAD S, TRANSFUS ME IN PRESS
  • [5] [Anonymous], 2000, ARCH IRAN MED
  • [6] [Anonymous], 2006, GOVARESH
  • [7] [Anonymous], 2004, GOVARESH
  • [8] [Anonymous], J IRANIAN MED COUNCI
  • [9] Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
    Bonino, F.
    Marcellin, P.
    Lau, G. K. K.
    Hadziyannis, S.
    Jin, R.
    Piratvisuth, T.
    Germanidis, G.
    Yurdaydin, C.
    Diago, M.
    Gurel, S.
    Lai, M-Y
    Brunetto, M. R.
    Farci, P.
    Popescu, M.
    McCloud, P.
    [J]. GUT, 2007, 56 (05) : 699 - 705
  • [10] Farajzadeh S, 2005, East Mediterr Health J, V11, P68